Wedbush Reaffirms Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a note issued to investors on Wednesday,Benzinga reports. They presently have a $36.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 58.45% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Guggenheim reissued a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded down $0.66 during trading hours on Wednesday, hitting $22.72. 43,258 shares of the company’s stock were exchanged, compared to its average volume of 244,145. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77. The stock has a market cap of $672.44 million, a price-to-earnings ratio of -9.09 and a beta of 1.82. The stock’s 50-day moving average is $22.65 and its 200-day moving average is $24.97.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. Equities research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Jane Street Group LLC bought a new position in Dianthus Therapeutics in the third quarter valued at approximately $556,000. Barclays PLC raised its holdings in shares of Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after acquiring an additional 33,185 shares during the period. HighVista Strategies LLC acquired a new position in Dianthus Therapeutics in the 3rd quarter worth $542,000. State Street Corp increased its holdings in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 142.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after purchasing an additional 97,362 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.